MRKR Projected Dividend Yield

Marker Therapeutics Inc ( NASDAQ : MRKR )

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. Co. specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumors associated antigens (TAAs), which are tumor targets, and kill tumor cells expressing those targets.

21 YEAR PERFORMANCE RESULTS